---
title: "Vertex EVP, Chief Commercial Officer Duncan McKechnie sells USD 799,779 of Vertex common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291972157.md"
description: "Vertex Pharmaceuticals Executive Vice President and Chief Commercial Officer Duncan McKechnie sold 1,541 common shares on July 2 at $519 per share, totaling approximately $799,779. Following the transaction, he retained a holding of 11,001 shares. The information was published via EDGAR by Vertex Pharmaceuticals."
datetime: "2026-07-07T20:08:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291972157.md)
  - [en](https://longbridge.com/en/news/291972157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291972157.md)
---

# Vertex EVP, Chief Commercial Officer Duncan McKechnie sells USD 799,779 of Vertex common shares

-   Vertex EVP and Chief Commercial Officer Duncan McKechnie sold 1,541 common shares on July 2 at USD 519. \* He held 11,001 shares following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vertex Pharmaceuticals Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000875320-26-000243), on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex Pharmaceuticals just made a $10 billion acquisition worth watching](https://longbridge.com/en/news/293142937.md)
- [Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal Plans](https://longbridge.com/en/news/293268909.md)
- [ImageneBio Principal Accounting Officer Robert B. Lally sells USD 17,350 of common shares](https://longbridge.com/en/news/293272951.md)
- [Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares](https://longbridge.com/en/news/293268525.md)
- [Incannex starts screening patients in Phase 2 DReAMzz trial of IHL-42X for sleep apnea](https://longbridge.com/en/news/293607970.md)